Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Embattled OccuLogix falls foul of Nasdaq

This article was originally published in Clinica

Executive Summary

Troubled ophthalmic device company OccuLogix is to see its shares delisted from the Nasdaq Capital Market, with effect from September 18. The Toronto, Ontario-based company had failed to comply with the stock exchange's listing requirements, namely the minimum stockholders' equity and bid price. OccuLogix's shares have been trading consistently below the $1-mark for over a year. The firm said it intends to ask the Nasdaq listing review panel for more time to regain compliance. In the meantime, it will transfer trading of its shares from the Nasdaq to the Over-the-Counter Bulletin Board (OTCBB), on or prior to September 18.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043206

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel